secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950170-25-004523
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma: setrusumab Phase 3 Orbit 2nd interim analysis mid-2025; alvelestat gets positive EMA orphan opinion
--------------------------------------------------------------------------------

- Phase 3 Orbit study of setrusumab in OI progressing to second interim analysis expected mid-2025; final analysis possible Q4 2025.
- Alvelestat receives positive EMA COMP opinion for Orphan Designation; European Commission final decision expected Q1 2025.
- Cash runway reaffirmed into 2027, funding through multiple key inflection points including setrusumab milestones.
- Cosmic study in OI patients aged 2 to <7 years continuing; data will be evaluated with Orbit analyses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000095017025004523/0000950170-25-004523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000095017025004523/mreo-20250112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer